Apoptosis rate and transcriptional response of pancreatic islets exposed to the PPAR gamma agonist Pioglitazone

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Lamounier, Rodrigo N ^a,b   Coimbra, Cassio N ^a,c   White, Peter ^b   Costal, Flavia L ^a   Oliveira, Leonardo S ^a,c   Giannella Neto, Daniel ^d   Kaestner, Klaus H ^b   Corrêa Giannella, Maria Lúcia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SANTO AMARO   (Brazil)

^d UNIVERSIDADE NOVE DE JULHO   (Brazil)

Author keywords

Apoptosis; Gene expression; Islets; Pioglitazone; PPAR

Indexed keywords

CASPASE 3; GLUCOSE; PIOGLITAZONE; PROTEIN BCL 2; RNA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CONCENTRATION (PARAMETERS); GENE EXPRESSION PROFILING; HYPERGLYCEMIA; INSULIN RELEASE; LIPID METABOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84871995957     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-1     Document Type: Article

References (49)

1. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Kahn SE, Diabetologia 2003 46 3 19 12637977 (Pubitemid 36237741)
2. The natural history of insulin secretory disfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Weyer C, Bogardus C, Mott DM, Pratley RE, J Clin Invest 1999 104 787 794 10.1172/JCI7231 10491414 (Pubitemid 29536364)
3. Insulin Sensitizers. Zangeneh F, Kudva YC, Basu A, Mayo Clin Proc 2003 78 471 479 10.4065/78.4.471 12683699 (Pubitemid 36373948)
4. Preservation of Pancreatic β-Cell Function and Prevention of Type 2 Diabetes by Pharmacological Treatment of Insulin Resistance in High-Risk Hispanic Women. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP, Diabetes 2002 51 2796 2803 10.2337/diabetes.51.9.2796 12196473 (Pubitemid 34970933)
5. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Miyazaki CY, Matsuda M, DeFronzo R, Diabetes Care 2002 25 517 523 10.2337/diacare.25.3.517 11874940 (Pubitemid 41103346)
6. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. Smith SA, Porter LE, Biswas N, Freed MI, J Clin Endocrinol Metabol 2004 89 6048 6053 10.1210/jc.2004-0705 (Pubitemid 39628413)
7. Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Finegood DT, McArthur MD, Kojwang D, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE, Diabetes 2001 50 1021 1029 10.2337/diabetes.50.5.1021 11334404 (Pubitemid 32374532)
8. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH, Proc Natl Acad Sci 1999 96 11513 11518 10.1073/pnas.96.20. 11513 10500208 (Pubitemid 29487412)
9. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor gamma- deficient mice on a high-fat diet. Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T, Diabetes 2004 53 2844 2854 10.2337/diabetes.53.11.2844 15504964 (Pubitemid 39425909)
10. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. Shimabukuro M, Zhou Y, Lee Y, Unger RH, J Biol Chem 1998 273 6 3547 3550 10.1074/jbc.273.6.3547 9452481 (Pubitemid 28109778)
11. Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. Saitoh Y, Chun-ping C, Noma K, Ueno H, Mizuta M, Nakazato M, Diabetes Obes Metab 2008 10 7 564 573 10.1111/j.1463-1326.2007. 00749.x 17593232 (Pubitemid 351850900)
12. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC, Diabetes 2003 52 102 110 10.2337/diabetes.52.1.102 12502499 (Pubitemid 36042113)
13. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Kashyap S, Belfort R, Castaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K, Diabetes 2003 52 2461 2474 10.2337/diabetes.52.10.2461 14514628 (Pubitemid 37210533)
14. Beta-cell preservation with thiazolidinediones. Campbell IW, Mariz S, Diabetes Res Clin Pract 2007 76 163 176 10.1016/j.diabres.2006.08.015 17052795 (Pubitemid 46402950)
15. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA, J Clin Endocrinol Metabol 2004 89 5059 5066 10.1210/jc.2004-0446 (Pubitemid 39391449)
16. Mechanism for antioxidative effects of thiazolidinediones in pancreatic β-cells. Chung SS, Kim M, Lee JS, Ahn BY, Jung HS, Lee HM, Park KS, Am J Physiol Endocrinol Metab 2011 301 5 912 E921 10.1152/ajpendo.00120.2011 21846907
17. PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress. Kono T, Ahn G, Moss DR, Gann L, Zarain-Herzberg A, Nishiki Y, Fueger PT, Ogihara T, Evans-Molina C, Mol Endocrinol 2012 26 2 257 271 10.1210/me.2011-1181 22240811
18. Troglitazone does not protect rat pancreatic β cells against free fatty acid-induced cytotoxicity. Cnop M, Hannaert JC, Pipeleers DG, Biochem Pharmacol 2002 63 1281 1285 10.1016/S0006-2952(02)00860-2 11960604 (Pubitemid 34311996)
19. PPAR-gamma overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells. Nakamichi Y, Kikuta T, Ito E, Ohara-Imaizumi M, Nishiwaki C, Ishida H, Nagamatsu S, Biochem Biophys Res Commun 2003 306 4 832 836 10.1016/S0006- 291X(03)01045-3 12821117 (Pubitemid 36776206)
20. Method for the isolation of intact islets of Langerhans from the rat pancreas. Lacy PE, Kostianovsky M, Diabetes 1967 16 35 39 5333500
21. Identification of transcriptional networks during liver regeneration. White P, Brestelli JE, Kaestner KH, Greenbaum LE, J Biol Chem 2005 280 3715 3722 15546871 (Pubitemid 40223839)
22. Transcriptional Program of the Endocrine Pancreas in Mice and Humans. Kaestner KH, Lee CS, Scearce LM, Brestelli JE, Arsenlis A, Le PP, Lantz KA, Crabtree J, Pizarro A, Mazzarelli J, Pinney D, Fischer S, Manduchi E, Stoeckert CJ Jr, Gradwohl G, Clifton SW, Brown JR, Inoue H, Cras-Méneur C, Permutt MA, Diabetes 2003 52 1604 1610 10.2337/diabetes.52.7.1604 12829622 (Pubitemid 36792446)
23. Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments. Smyth GK, Stat Appl Genet Mol Biol 2004 3 1 Article 3. Available at: http://www.bepress.com/sagmb/vol3/iss1/art3. (Accessed on December, 15th, 2007)
24. Significance analysis of microarrays applied to the ionizing radiation response. Tusher VG, Tibshirani R, Chu G, Proc Natl Acad Sci U S A 2001 98 9 5116 5121 10.1073/pnas.091062498 11309499 (Pubitemid 32397092)
25. RAD and the RAD Study-Annotator: an approach to collection, organization and exchange of all relevant information for high-throughput gene expression studies. Manduchi E, Grant GR, He H, Liu J, Mailman MD, Pizarro AD, Whetzel PL, Stoeckert CJ Jr, Bioinformatics 2004 20 4 452 459 10.1093/bioinformatics/btg428 14990441 (Pubitemid 38344324)
26. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F, Genome Biol 2002 3 7 esearch0034.1 research0034.11 10.1186/gb-2002-3-7-research0034
27. Analysis of relative gene expression data using real-time quantitative PCR and the 2 Delta Delta C T method. Livak KJ, Schmittgen TD, Methods 2001 25 402 408 10.1006/meth.2001.1262 11846609 (Pubitemid 34164012)
28. Impact of PPARgamma overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays. Parton LE, Diraison F, Neill SE, Ghosh SK, Rubino MA, Bisi JE, Briscoe CP, Rutter GA, Am J Physiol Endocrinol Metab 2004 287 3 390 E404 10.1152/ajpendo.00016.2004 15126236 (Pubitemid 39095872)
29. Peroxisomal Proliferator-Activated Receptor-γ Upregulates Glucokinase Gene Expression in β-cells. Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK, Lee NT, Choi KY, Kim KS, Ahn YH, Diabetes 2002 51 676 685 10.2337/diabetes.51.3.676 11872666 (Pubitemid 34760175)
30. Role and mechanism of rosiglitazone on the impairment of insulin secretion induced by free fatty acids on isolated rat islets. Tian JY, Li G, Gu YY, Zhang HL, Zhou WZ, Wang X, Zhu HD, Luo TH, Luo M, Chin Med J 2006 119 7 574 580 16620699 (Pubitemid 43796863)
31. Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Risérus U, Tan GD, Fielding BA, Neville MJ, Currie J, Savage DB, Chatterjee VK, Frayn KN, O'Rahilly S, Karpe F, Diabetes 2005 54 5 1379 1384 10.2337/diabetes.54.5.1379 15855323 (Pubitemid 40586667)
32. Adipogenesis and Obesity: Rounding Out the Big Picture. Spiegelman BM, Flier JS, Cell 1996 87 377 389 10.1016/S0092-8674(00)81359-8 8898192 (Pubitemid 26374313)
33. Regulation of Peroxisome Proliferator-Activated Receptor g Expression by Adipocyte Differentiation and Determination Factor 1/Sterol Regulatory Element Binding Protein 1: Implications for Adipocyte Differentiation and Metabolism. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, Fruchart JC, Briggs M, Spiegelman BM, Auwerx J, Molecular Cell Biology 1999 19 8 5495 5503 (Pubitemid 29339907)
34. Crucial Step in Cholesterol Homeostasis: Sterols Promote Binding of SCAP to INSIG-1, a Membrane Protein that Facilitates Retention of SREBPs in ER. Yang T, Espenshade PJ, Wright ME, Yabe D, Gong Y, Aebersold R, Goldstein JL, Brown MS, Cell 2002 110 489 500 10.1016/S0092-8674(02)00872-3 12202038 (Pubitemid 35232292)
35. Hormone-Sensitive Lipase Has a Role in Lipid Signaling for Insulin Secretion but Is Nonessential for the Incretin Action of Glucagon-Like Peptide 1. Peyot ML, Nolan CJ, Soni K, Joly E, Lussier R, Corkey BE, Wang SP, Mitchell GA, Prentki M, Diabetes 2004 53 1733 1742 10.2337/diabetes.53.7.1733 15220197 (Pubitemid 38857031)
36. Glucose-Regulated Gene Expression Maintaining the Glucose-Responsive State of β-Cells. Schuit F, Flamez D, De Vos A, Pipeleers D, Diabetes 2002 51 Suppl. 3 326 S332 12475771
37. In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. Miao F, Gonzalo IG, Lanting L, Natarajan R, J Biol Chem 2004 279 17 18091 18097 10.1074/jbc.M311786200 14976218 (Pubitemid 38560579)
38. Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure. Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garmey JC, Deering TG, Keller SR, Maier B, Mirmira RG, Molecular Cell Biology Apr 2009 29 8 2053 2067 10.1128/MCB.01179-08
39. Heme oxygenase-1 carbon monoxide: from basic science to therapeutic applications. Ryter SW, Alam J, Choi AM, Physiol Rev 2006 86 583 650 10.1152/physrev.00011.2005 16601269
40. Repair of pancreatic ß-cells: a relevant phenomenon in early IDDM. Eizirik DL, Sandler S, Palmer JP, Diabetes 1993 42 1383 1389 10.2337/diabetes.42.10.1383 8375580
41. Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities. Abaraviciene SM, Lundquist I, Salehi A, Cell Mol Life Sci 2008 65 14 2256 2265 10.1007/s00018-008-8100-8 18560759
42. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity. Ghanaat-Pour H, Sjöholm A, Diabetes & Metabolism Rev 2009 25 2 163 184 10.1002/dmrr.896 23451284
43. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma in the modulation of insulin secretion. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S, Am J Physiol Endocrinol Metab 2004 286 4 560 E567 10.1152/ajpendo.00561.2002 14625208 (Pubitemid 38374953)
44. PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets. Vandewalle B, Moerman E, Lefebvre B, Defrance F, Gmyr V, Lukowiak B, Kerr Conte J, Pattou F, Biochem Biophys Res Commun 2008 366 4 1096 1101 10.1016/j.bbrc.2007.12.088 18155663
45. Troglitazone (CS-045) inhibits beta-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells Endocrinology. Ohtani KI, Shimizu H, Sato N, Mori M, Jan 1998 139 1 172 178 (Pubitemid 28166306)
46. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist. Kanda Y, Shimoda M, Hamamoto S, Tawaramoto K, Kawasaki F, Hashiramoto M, Nakashima K, Matsuki M, Kaku K, Am J Physiol Endocrinol Metab 2010 298 2 278 E286 10.1152/ajpendo.00388.2009 19920213
47. Chronic treatment with the thiazolidinedione, MCC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker Diabetic Fatty rat. Pickavance LC, Widdowson PS, Foste JR, Williams G, Wilding JPH, Int J Exp Pathol 2003 84 83 89 10.1046/j.1365-2613. 2003.00337.x 12801282 (Pubitemid 36754273)
48. Activation of Peroxisome Proliferator-Activated Receptor-γ by Rosiglitazone Protects Human Islet Cells against Human Islet Amyloid Polypeptide Toxicity by a Phosphatidylinositol 3-Kinase-Dependent Pathway. Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC, J Clin Endocrinol Metabol 2005 90 12 6678 6686 10.1210/jc.2005-0079 (Pubitemid 41759332)
49. Insulin-sparing effects of roglitazone in rat pancreatic islets. Bollheimer LC, Troll S, Landauer H, Wrede CE, Schölmerich J, Buettner R, J Mol Endocrinol 2003 31 1 61 69 10.1677/jme.0.0310061 12914525 (Pubitemid 37063079)